Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-30 11:07:15 - browse：64817

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Phenylephrine and the overlooked value of the placebo effect

focus

entertainment

WSS

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Body of missing toddler recovered in Delaware River days after flood: Police

Caitlin Bernard's story shows physicians can't shy from advocacy

A virus, fished out of a lake, may have saved a man’s life

Histogen: Failed biotech offers rare public look inside

Stroke deaths set to near 10 million globally by 2050

hotspot

Wikipedia

knowledge

Drug repurposing or repositioning? The language matters

Sana to lay off nearly a third of staff, de

Malaria cases in Florida and Texas: Here’s what you need to know

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Cancer drug shortages should be causing more outrage

Court strikes down limits on filming of police in Arizona

BioMarin wins approval for gene therapy to treat hemophilia A

Bill would stop addiction treatment from triggering child abuse inquiry

After affirmative action ruling, medical educators look to 'holistic review'

Why age limits for politicians are a terrible idea

hotspot

Organ transplantation is at a crossroads. Major reform is needed

What to expect at HLTH 2023, the health care industry conference

Body of missing toddler recovered in Delaware River days after flood: Police

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Russian special forces kill a gunman who broke into a private house near Moscow

Senate panel eyes new effort on drug shortages

focus

focus

entertainment

focus